New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
05:55 EDTNVS, NVS, PFE, PFE, JNJ, JNJ, RHHBY, RHHBY, VOD, VOD, WBMD, WBMD, DB, DB, SNY, SNY, AZN, AZN, MRK, MRK, GSK, GSK, AGEN, AGENFinancial Times to hold a conference
Global Pharmaceutical & Biotechnology Conference 2012 is being held in London on December 4-5.
News For NVS;GSK;MRK;AZN;SNY;DB;WBMD;VOD;RHHBY;JNJ;PFE;AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 13, 2014
07:15 EDTJNJNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
07:12 EDTGSKOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
October 12, 2014
19:36 EDTDBDeutsche Bank loses traders as it enforces behavior policy, FT says
Subscribe for More Information
14:42 EDTDBDeutsche Bank's provisions for legal costs may rise to $8.8B, Bloomberg says
Deutsche Bank's allocation for potential legal costs may rise to as much as $8.8B, says Bloomberg, citing a report from Spiegel. The banks legal costs which were 3B euros last year are impeding its efforts to build capital and increase returns for investors, added Bloomberg. Reference Link
October 10, 2014
16:18 EDTAGENAgenus files $150M mixed securities shelf
10:01 EDTJNJOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:13 EDTDBEBA says EU stress test results to be published October 26
Subscribe for More Information
08:19 EDTJNJMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
08:15 EDTJNJJohnson & Johnson reports additional data from ATTAIN study
Subscribe for More Information
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
07:07 EDTJNJJohnson & Johnson upgraded to Neutral from Underperform at Credit Suisse
Subscribe for More Information
06:27 EDTJNJJohnson & Johnson upgraded to Neutral from Underperform at Credit Suisse
05:13 EDTNVSNovartis reports new analyses of AIN457 Phase III data show consistent efficacy
Novartis announced that new analyses of AIN457 Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity. Secukinumab's new mode of action stops interleukin-17A, which plays a central role in the development of psoriasis. In the analyses, the majority of patients across two disease severity subgroups, including those with severe psoriasis, experienced complete clear to almost clear skin measured as 100 or 90% reduction of respective baseline PASI, or Psoriasis Area and Severity Index. Skin clearance was sustained through one year of treatment. This is important as historically, psoriasis patients' disease severity at the start of treatment has been shown to negatively impact their response to other therapies. Disease severity subgroups were PASI less than or equal to 20 and PASI greater than 20. PASI measures redness, scaling and thickness of psoriatic plaques and the impact in regions of the body. These findings reconfirm the significantly better responses seen in the published FIXTURE study, where secukinumab showed superiority to Enbrel, a standard of care anti-TNF medication.
October 9, 2014
10:00 EDTVODOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:32 EDTMRKMerck HCV solutions becoming more credible, says Bernstein
Subscribe for More Information
08:27 EDTVODVodafone downgraded to Reduce from Neutral at Nomura
Subscribe for More Information
08:10 EDTAZNAstraZeneca reports Phase IIb study of benralizumab met primary endpoint
Subscribe for More Information
07:02 EDTGSKIsis Pharmaceuticals receives $18M milestone payment from GlaxoSmithKline
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use